СOMPARATIVE ASSESSMENT OF CLINICAL, COGNITIVE, AND BIOCHEMICAL CHARACTERISTICS IN PATIENTS WITH PARKINSON’S DISEASE AND TYPE 2 DIABETES MELLITUS

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder marked by progressive motor dysfunction and cognitive impairment. Type 2 diabetes mellitus (T2DM) is known to exacerbate systemic inflammation and oxidative stress, which could accelerate neurodegenerative processes in PD. This study aims to compare motor and cognitive symptoms, biochemical markers, and disease progression in PD patients with and without comorbid T2DM.

The purpose of study:This study provides a comparative analysis of motor and non-motor symptoms, cognitive dysfunction, and biochemical markers in Parkinson’s disease (PD) patients with and without comorbid type 2 diabetes mellitus (T2DM). It highlights the  effects of T2DM on PD progression, emphasizing the necessity for integrated management approaches.

Materials and Methods:

A comparative, observational study was conducted on 54 patients with PD, including 22 with comorbid T2DM and 32 with PD only. All participants were selected from the neurology department of the Tashkent Medical Academy. Motor symptoms were assessed using the MDS-UPDRS scale, cognitive function with the PD-CRS scale, and biochemical markers (glucose, fibrinogen, hematocrit) were measured.

Results:
PD patients with T2DM showed significantly worse motor dysfunction (MDS-UPDRS scores: 134.8 ± 6.1 vs. 108.2 ± 5.4), cognitive decline (PD-CRS scores: 65.1 ± 2.1 vs. 80.3 ± 1.7), and elevated biochemical markers such as glucose (9.3 ± 0.55 mmol/L vs. 4.7 ± 0.12 mmol/L) and fibrinogen levels (300.3 ± 9.3 mg/dL vs. 263.4 ± 9.4 mg/dL). The Hoehn and Yahr stage was also higher in the T2DM group (3.1 ± 0.14 vs. 2.7 ± 0.09).

Discussion:
The findings suggest that T2DM worsens the progression of PD, leading to more severe motor and cognitive impairments. Elevated glucose and fibrinogen levels may contribute to these exacerbated symptoms.